Teleflex Inc. is going big on its investment in the business of helping people reduce their size with an agreement to acquire Standard Bariatrics Inc. for an upfront cash payment of $170 million with contingent payments of $130 million upon achievement of specified commercial milestones. The companies expect to close the transaction early in the fourth quarter of 2022. Standard Bariatrics produces a novel clamp and staple system for gastric sleeve surgery, the Titan sleeve gastrectomy stapler (SGS).

Precision Diabetes Inc. (PDI) entered an exclusive agreement with Dxgen Corp. to introduce and distribute the Epithod Autodx point-of-care analyzer and multiple diabetes tests that run on the system within the U.S. The first available tests will include hemoglobin A1c, C-reactive protein and albumin, with the portfolio of tests expected to grow quickly.

Boston Scientific Corp. acquired privately held Obisidio Inc., adding the company’s gel embolic material (GEM) technology to its portfolio. GEM is a ready-to-use, semi-solid material that conforms to the vasculature in which it is placed to immediately obstruct or reduce blood flow to a tumor or abnormality or stop hemorrhaging.

Becton, Dickinson and Co. and Accelerate Diagnostics Inc. joined forces to knock out sepsis and put patients on the path to recovery in hours, not days.

Grand Pharmaceutical Group Ltd. acquired about 11% of the equity of Xeltis AG and will introduce Xeltis’ Axess to the greater China markets. Axess is a restorative hemodialysis access graft used for arteriovenous graft (AVG) patients with end-stage renal disease (ESRD).

Medtronic plc inked an agreement to combine its patient care technologies with a wearable, remote monitoring platform developed by Pasadena, Calif.-based Rockley Photonics Inc. The Bioptx contains compact, photonics-based sensors inside a wristband to monitor a range of biomarkers beyond standard blood pressure, heart rate, pulse oximetry and glucose levels, making Rockley and Medtronic’s development partnership, said Rockley Chair and CEO Andrew Rickman, “a terrific match.”

Bio-Rad Laboratories Inc. signed a $170 million deal to acquire all the outstanding shares of molecular diagnostics subsidiary Curiosity Diagnostics SpZoo from Scope Fluidics SA. The deal consists of approximately $100 million in cash and up to $70 million in future milestone payments. The pre-commercial platform company is the developer of a CE-marked 15-minute point-of-care (POC) rapid PCR system which tests for SARS-CoV-2 virus and methicillin-resistant or-sensitive Staphylococcus aureus bacteria (MRSA/MSSA).

Conmed Corp. is acquiring soft tissue augmentation company Biorez Inc. for $85 million and up to an additional $165 million in growth-based earnout payments over a four-year period. The New Haven, Conn.-based company develops Biobrace, a bioinductive implant which promotes soft tissue healing in tendon and ligament injuries. The implant is cleared for use by the U.S. FDA in two product sizes.

Perkinelmer Inc. agreed to divest three businesses in a sale to private equity firm New Mountain Capital for $2.45 billion in cash to create a “pure-play, high growth, high margin life sciences and diagnostics company with unique scale,” said Perkinelmer president and CEO Prahlad Singh.